$5650 | Single User
$6650 | Multi User
$8150 | Corporate License
$10000 | Global License

Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020
[Lowest Price Guaranteed: $5,650]

Published by MarketsandMarkets: 10 Jun 2015 | 41623 | In Stock

Introduction

According to the CDC, cancer is the second leading cause of mortality, causing ~584,881 deaths worldwide in 2013. Early diagnosis is the key to prevent the rising number of cancer-related deaths. The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms such as next-generation sequencing, DNA microarrays, and polymerase chain reaction (PCR). Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have augmented the growth of the cancer diagnostics market.

The instrument-based cancer diagnostics segment accounted for the largest share of the global the cancer diagnostics market, by technology, while breast cancer accounted for the largest share of the cancer diagnostics applications market, in 2014.

North America accounted for the largest share of the global cancer diagnostics market, followed by Europe, Asia, and the Rest of the World (RoW). In the coming years, the cancer diagnostics market is expected to experience the highest growth rate in the Asian region, with emphasis on India and China. These countries are expected to serve as revenue pockets for companies operating in the cancer diagnostics market.

The global cancer diagnostics market witnesses high competitive intensity as there are several big and many small firms operating in different segments of the market. These companies adopt various strategies (agreements/partnerships/joint ventures/collaborations, new product launches, geographical expansions, and acquisitions) to increase their market shares and establish a strong foothold in the global market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the cancer diagnostics market. The report analyzes cancer diagnostics by technology, application, and geography

• Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the cancer diagnostics market

• Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various cancer diagnostic technologies across regions

• Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the cancer diagnostics market

• Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the cancer diagnostics market

Table of Contents
for Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020

  • TABLE OF CONTENTS

    1 INTRODUCTION 18

    1.1 OBJECTIVES OF THE STUDY 18

    1.2 MARKET DEFINITION 18

    1.3 MARKET SCOPE 19

    1.3.1 MARKETS COVERED 19

    1.3.2 YEARS CONSIDERED FOR THE STUDY 21

    1.4 CURRENCY 21

    1.5 LIMITATIONS 21

    1.6 STAKEHOLDERS 21

    2 RESEARCH METHODOLOGY 22

    2.1.1 RESEARCH METHODOLOGY STEPS 22

    2.1.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 23

    2.1.2.1 Secondary Research 23

    2.1.3 KEY DATA FROM SECONDARY SOURCES 23

    2.1.3.1 Primary research 24

    2.1.3.2 Key industry insights 24

    2.1.4 KEY DATA FROM PRIMARY SOURCES 25

    2.1.5 KEY INSIGHTS FROM PRIMARY SOURCES 26

    2.1.6 MARKET SIZE ESTIMATION METHODOLOGY 26

    2.1.7 RESEARCH DESIGN 28

    2.1.8 MARKET DATA VALIDATION AND TRIANGULATION 28

    2.1.9 ASSUMPTIONS FOR THE STUDY 29

    3 EXECUTIVE SUMMARY 30

    3.1 INTRODUCTION 30

    3.2 CURRENT SCENARIO 31

    3.3 FUTURE OUTLOOK 31

    3.4 CONCLUSION 33

    4 PREMIUM INSIGHTS 34

    4.1 GLOBAL CANCER DIAGNOSTICS MARKET 34

    4.2 REGIONAL SNAPSHOT OF THE CANCER DIAGNOSTICS MARKET 36

    4.3 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY (2015 VS. 2020) 36

    5 MARKET OVERVIEW 37

    5.1 INTRODUCTION 38

    5.2 MARKET DYNAMICS 38

    5.2.1 DRIVERS 39

    5.2.1.1 Rising prevalence of cancer 39

    5.2.1.2 Technological Advancements 39

    5.2.1.3 Initiatives undertaken by governments and global health organizations to spread awareness about cancer 39

    5.2.1.4 Growth in the number of private diagnostic centers 40

    5.2.1.5 Public-private partnerships to enhance the infrastructure of diagnostic imaging centers 40

    5.2.1.6 FDA support for biomarker development 41

    5.2.1.7 Launch of new flow cytometry reagents for diagnostics and drug discovery 41

    5.2.2 RESTRAINTS 43

    5.2.2.1 High capital investments & low benefit-cost ratio for biomarkers 43

    5.2.2.2 Shortage of helium 43

    5.2.2.3 High cost of diagnostic imaging systems affecting their rate of adoption in emerging markets 43

    5.2.2.4 Risk of high radiation exposure likely to limit the usage of CT scanners 44

    5.2.2.5 Dearth of skilled and experienced personnel 44

    5.2.3 OPPORTUNITIES 46

    5.2.3.1 Personalized medicine 46

    5.2.3.2 Development of mass cytometry and the combination of cell-and bead-based flow cytometry technologies 46

    5.2.3.3 Companion Diagnostics 47

    5.2.3.4 Improving healthcare infrastructure in emerging markets 47

    5.2.3.5 Miniaturized and technologically advanced devices 48

    5.2.4 CHALLENGES 49

    5.2.4.1 Stringent regulatory guidelines 49

    5.2.4.2 Hospital budget cuts a key challenge to market players 50

    5.2.4.3 Increasing adoption of refurbished diagnostic imaging systems 50

    6 GLOBAL CANCER DIAGNOSTICS MARKET, BY APPLICATION 52

    6.1 INTRODUCTION 53

    6.1.1 BREAST CANCER 55

    6.1.2 LUNG CANCER 56

    6.1.3 COLORECTAL CANCER 57

    6.1.4 MELANOMA 58

    6.1.5 OTHER CANCERS 59

    7 GLOBAL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 61

    7.1 INTRODUCTION 62

    7.2 PLATFORM-BASED DIAGNOSTICS 63

    7.2.1 POLYMERASE CHAIN REACTION (PCR) 64

    7.2.2 IN SITU HYBRIDIZATION (ISH) 66

    7.2.3 IMMUNOHISTOCHEMISTRY (IHC) 67

    7.2.4 NEXT-GENERATION SEQUENCING (NGS) 69

    7.2.5 MICROARRAYS 70

    7.2.6 FLOW CYTOMETRY 71

    7.2.7 OTHER TECHNOLOGIES 73

    7.3 INSTRUMENT-BASED 74

    7.3.1 DIAGNOSTIC IMAGING 74

    7.3.1.1 Magnetic resonance imaging (MRI) 76

    7.3.1.2 Computed tomography (CT) 77

    7.3.1.3 Positron emission tomography (PET) 78

    7.3.1.3.1 Standalone positron emission tomography 79

    7.3.1.3.2 Hybrid positron emission tomography 80

    7.3.1.4 Mammography 81

    7.3.1.5 Ultrasound 81

    7.3.2 BIOPSIES 82

    8 CANCER DIAGNOSTICS MARKET, BY REGION 85

    8.1 INTRODUCTION 86

    8.2 NORTH AMERICA 86

    8.2.1 U.S. 89

    8.2.1.1 GOVERNMENT INITIATIVES 89

    8.2.1.2 INCREASE IN CANCER INCIDENCE 90

    8.2.2 CANADA 92

    8.2.2.1 HIGH INCIDENCE OF CANCER 92

    8.2.2.2 GOVERNMENT FUNDING 92

    8.3 EUROPE 94

    8.3.1 FUNDING FOR CANCER DIAGNOSTICS RESEARCH 95

    8.3.2 EU-5 (U.K., GERMANY, FRANCE, ITALY, SPAIN) 97

    8.3.2.1 STRONG GOVERNMENT SUPPORT 97

    8.3.2.2 RESEARCH COLLABORATIONS 98

    8.3.2.3 INCREASE IN DIAGNOSTIC IMAGING CENTERS 99

    8.3.2.4 RISING PUBLIC AND PRIVATE INVESTMENTS 99

    8.3.3 REST OF EUROPE (ROE) 101

    8.3.3.1 AGING POPULATION 101

    8.3.3.2 CONFERENCES BOOSTING AWARENESS 101

    8.3.3.3 GOVERNMENT INVESTMENTS IN RUSSIA 102

    8.4 ASIA 104

    8.4.1 CHINA 107

    8.4.1.1 EXPANSION OF INTERNATIONAL PLAYERS 107

    8.4.1.2 AGING POPULATION AND INCREASING CANCER INCIDENCE 108

    8.4.2 JAPAN 110

    8.4.2.1 AGING POPULATION AND HIGH HEALTHCARE EXPENDITURE IN JAPAN 110

    8.4.3 INDIA 112

    8.4.3.1 INCREASING FOCUS OF INTERNATIONAL PLAYERS ON INDIA 112

    8.4.4 REST OF ASIA 114

    8.4.4.1 PRESENCE OF INTERNATIONAL PLAYERS BOOSTING MARKET GROWTH 114

    8.5 REST OF THE WORLD (ROW) 116

    8.5.1 GOVERNMENT INITIATIVES BOOSTING DEMAND FOR CANCER DIAGNOSTICS 117

    8.5.2 AGING POPULATION, PRESENCE OF INTERNATIONAL PLAYERS 117

    8.5.3 INCREASE IN CANCER INCIDENCES AND RISING GOVERNMENT EXPENDITURE 118

    8.5.4 GOVERNMENT INITIATIVES TO IMPROVE HEALTHCARE INFRASTRUCTURE 118

    9 COMPETITIVE LANDSCAPE 121

    9.1 MARKET SHARE ANALYSIS 121

    9.2 COMPETITIVE LANDSCAPE: OVERVIEW 129

    9.3 COMPETITIVE SITUATION AND TRENDS 131

    9.3.1 COLLABORATIONS/AGREEMENTS/PARTNERSHIPS/ALLIANCES 132

    9.3.2 NEW PRODUCT LAUNCHES 133

    9.3.3 ACQUISITIONS 134

    9.3.4 EXPANSION 135

    9.3.5 OTHERS 136

    10 COMPANY PROFILES 137

    10.1 INTRODUCTION 137

    10.3 BECTON, DICKINSON AND COMPANY 142

    10.3.1 BUSINESS OVERVIEW 142

    10.3.2 PRODUCT PORTFOLIO 143

    10.3.3 KEY STRATEGY 143

    10.3.4 RECENT DEVELOPMENTS 144

    10.4 GE HEALTHCARE (A SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 145

    10.4.1 BUSINESS OVERVIEW 145

    10.4.2 PRODUCT PORTFOLIO 146

    10.4.3 KEY STRATEGY 146

    10.4.4 RECENT DEVELOPMENTS 147

    10.5 ABBOTT LABORATORIES 148

    10.5.1 BUSINESS OVERVIEW 148

    10.5.2 PRODUCT PORTFOLIO 149

    10.5.3 KEY STRATEGY 149

    10.5.4 RECENT DEVELOPMENTS 149

    10.6 ROCHE HOLDING AG 150

    10.6.1 BUSINESS OVERVIEW 150

    10.6.2 PRODUCT PORTFOLIO 151

    10.6.3 KEY STRATEGY 151

    10.6.4 RECENT DEVELOPMENTS 152

    10.7 THERMO FISHER SCIENTIFIC, INC. 153

    10.7.1 BUSINESS OVERVIEW 153

    10.7.2 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT 153

    10.7.3 PRODUCT PORTFOLIO 154

    10.7.4 KEY STRATEGY 154

    10.7.5 RECENT DEVELOPMENTS 155

    10.8 AGILENT TECHNOLOGIES, INC. 156

    10.8.1 BUSINESS OVERVIEW 156

    10.8.2 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 156

    10.8.3 PRODUCT PORTFOLIO 157

    10.8.4 KEY STRATEGY 157

    10.8.5 RECENT DEVELOPMENTS 158

    10.9 ILLUMINA, INC. 159

    10.9.1 BUSINESS OVERVIEW 159

    10.9.2 PRODUCT PORTFOLIO 160

    10.9.3 KEY STRATEGY 160

    10.9.4 RECENT DEVELOPMENTS 161

    10.10 SIEMENS HEALTHCARE 162

    10.10.1 BUSINESS OVERVIEW 162

    10.10.2 PRODUCT PORTFOLIO 163

    10.10.3 KEY STRATEGY 163

    10.10.4 RECENT DEVELOPMENTS 164

    10.11 C.R. BARD, INC. 165

    10.11.1 BUSINESS OVERVIEW 165

    10.11.2 PRODUCT PORTFOLIO 166

    10.11.3 KEY STRATEGY 166

    10.11.4 RECENT DEVELOPMENTS 166

    11 APPENDIX 167

    11.1 DISCUSSION GUIDE 167

    11.2 COMPANY DEVELOPMENTS (2012-2015) 172

    11.2.1 QIAGEN N.V. 172

    11.2.2 BECTON, DICKINSON AND COMPANY 173

    11.2.3 GE HEALTHCARE 173

    11.2.4 ABBOTT LABORATORIES 174

    11.2.5 ROCHE HOLDING AG 174

    11.2.6 THERMO FISHER SCIENTIFIC, INC. 175

    11.2.7 AGILENT TECHNOLOGIES, INC. 176

    11.2.8 ILLUMINA, INC. 177

    11.2.9 SIEMENS HEALTHCARE 177

    11.3 AVAILABLE CUSTOMIZATIONS 178

    11.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 178

    11.5 RELATED REPORTS 180

List Of Tables
in Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020

LIST OF TABLES


TABLE 1 RISING PREVALENCE OF CANCER IS DRIVING THE GROWTH OF THE CANCER DIAGNOSTICS MARKET 41

TABLE 2 HIGH CAPITAL INVESTMENT RESTRAINING THE GROWTH OF CANCER DIAGNOSTICS MARKET 45

TABLE 3 EMERGING MARKETS PRESENT AN ARRAY OF OPPORTUNITIES FOR THE GROWTH OF THE CANCER DIAGNOSTICS MARKET 48

TABLE 4 STRINGENT REGULATORY GUIDELINES ARE A MAJOR CHALLENGE IN THE CANCER DIAGNOSTICS MARKET 51

TABLE 5 GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION,

2013–2020 ($MILLION) 54

TABLE 6 CANCER DIAGNOSTICS MARKET SIZE FOR BREAST CANCER, BY REGION,

2013–2020 ($MILLION) 55

TABLE 7 CANCER DIAGNOSTICS MARKET SIZE FOR LUNG CANCER, BY REGION,

2013–2020 ($MILLION) 57

TABLE 8 CANCER DIAGNOSTICS MARKET SIZE FOR COLORECTAL CANCER, BY REGION, 2013–2020 ($MILLION) 58

TABLE 9 CANCER DIAGNOSTICS MARKET SIZE FOR MELANOMA, BY REGION,

2013–2020 ($MILLION) 58

TABLE 10 CANCER DIAGNOSTICS MARKET SIZE FOR OTHER CANCERS, BY REGION,

2013–2020 ($MILLION) 60

TABLE 11 GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2013–2020 ($MILLION) 62

TABLE 12 GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2013–2020 ($MILLION) 63

TABLE 13 CANCER DIAGNOSTICS MARKET SIZE FOR PLATFORM-BASED DIAGNOSTICS,

BY REGION, 2013–2020 ($MILLION) 64

TABLE 14 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR PCR, BY REGION,

2013–2020 ($MILLION) 65

TABLE 15 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR PCR, BY APPLICATION,

2013–2020 ($MILLION) 65

TABLE 16 CANCER DIAGNOSTICS MARKET SIZE FOR IN SITU HYBRIDIZATION, BY REGION, 2013-2020 ($MILLION) 66

TABLE 17 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR IN SITU HYBRIDIZATION,

BY APPLICATION, 2013–2020 ($MILLION) 67

TABLE 18 CANCER DIAGNOSTICS MARKET SIZE FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2013–2020 ($MILLION) 68

TABLE 19 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR IMMUNOHISTOCHEMISTRY,

BY APPLICATION, 2013–2020 ($MILLION) 68

TABLE 20 CANCER DIAGNOSTICS MARKET SIZE FOR NGS, BY REGION,

2013–2020 ($MILLION) 69

TABLE 21 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR NGS, BY APPLICATION,

2013–2020 ($MILLION) 70

TABLE 22 CANCER DIAGNOSTICS MARKET SIZE FOR MICROARRAYS, BY REGION,

2013–2020 ($MILLION) 71

TABLE 23 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR MICROARRAYS,

BY APPLICATION, 2013–2020 ($MILLION) 71

TABLE 24 CANCER DIAGNOSTICS MARKET SIZE FOR FLOW CYTOMETRY, BY REGION,

2013–2020 ($MILLION) 72

TABLE 25 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR FLOW CYTOMETRY,

BY APPLICATION, 2013–2020 ($MILLION) 72

TABLE 26 CANCER DIAGNOSTICS MARKET SIZE FOR OTHER TECHNOLOGIES, BY REGION, 2013–2020 ($MILLION) 73

TABLE 27 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR OTHER TECHNOLOGIES,

BY APPLICATION, 2013–2020 ($MILLION) 73

TABLE 28 GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2013–2020 ($MILLION) 74

TABLE 29 CANCER DIAGNOSTICS MARKET SIZE FOR DIAGNOSTIC IMAGING, BY PRODUCT, 2013–2020 ($MILLION) 74

TABLE 30 CANCER DIAGNOSTICS MARKET SIZE FOR DIAGNOSTIC IMAGING, BY REGION, 2013–2020 ($MILLION) 75

TABLE 31 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR IMAGING, BY APPLICATION, 2013–2020 ($MILLION) 75

TABLE 32 CANCER DIAGNOSTICS MARKET SIZE FOR MRI, BY REGION,

2013–2020 ($MILLION) 77

TABLE 33 CANCER DIAGNOSTICS MARKET SIZE FOR CT, BY REGION, 2013–2020 ($MILLION) 78

TABLE 34 CANCER DIAGNOSTICS MARKET SIZE FOR PET, BY PRODUCT,

2013–2020 ($MILLION) 78

TABLE 35 CANCER DIAGNOSTICS MARKET SIZE FOR PET, BY REGION,

2013–2020 ($MILLION) 79

TABLE 36 CANCER DIAGNOSTICS MARKET SIZE FOR STANDALONE PET, BY REGION,

2013–2020 ($MILLION) 79

TABLE 37 CANCER DIAGNOSTICS MARKET SIZE FOR HYBRID PET, BY REGION,

2013–2020 ($MILLION) 80

TABLE 38 CANCER DIAGNOSTICS MARKET SIZE FOR MAMMOGRAPHY, BY REGION,

2013–2020 ($MILLION) 81

TABLE 39 CANCER DIAGNOSTICS MARKET SIZE FOR ULTRASOUND, BY REGION,

2013–2020 ($MILLION) 82

TABLE 40 CANCER DIAGNOSTICS MARKET SIZE FOR BIOPSY, BY REGION,

2013–2020 ($MILLION) 83

TABLE 41 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR BIOPSY, BY APPLICATION, 2013–2020 ($MILLION) 84

TABLE 42 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY,

2013—2020 ($MILLION) 87

TABLE 43 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,

2013—2020 ($MILLION) 87

TABLE 44 NORTH AMERICA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET,

BY TECHNOLOGY, 2013—2020 ($MILLION) 88

TABLE 45 NORTH AMERICA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET,

BY TECHNOLOGY, 2013—2020 ($MILLION) 88

TABLE 46 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION,

2013—2020 ($MILLION) 89

TABLE 47 U.S.: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 90

TABLE 48 U.S.: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 91

TABLE 49 U.S.: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 91

TABLE 50 CANADA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,

2013—2020 ($MILLION) 92

TABLE 51 CANADA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 93

TABLE 52 CANADA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 93

TABLE 53 EUROPE: CANCER DIAGNOSTICS MARKET, BY REGION, 2013—2020 ($MILLION) 95

TABLE 54 EUROPE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,

2013—2020 ($MILLION) 95

TABLE 55 EUROPE: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 96

TABLE 56 EUROPE: CANCER DIAGNOSTICS INSTRUMENT MARKET, BY TECHNOLOGY,

2013—2020 ($MILLION) 96

TABLE 57 EUROPE: CANCER DIAGNOSTICS MARKET, BY APPLICATION,

2013—2020 ($MILLION) 97

TABLE 58 EU-5: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 100

TABLE 59 EU-5: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 100

TABLE 60 EU-5: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 101

TABLE 61 ROE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 102

TABLE 62 ROE: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY,

2013—2020 ($MILLION) 103

TABLE 63 ROE: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 103

TABLE 64 ASIA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2013—2020 ($MILLION) 105

TABLE 65 ASIA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 105

TABLE 66 ASIA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 106

TABLE 67 ASIA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 106

TABLE 68 ASIA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2013—2020 ($MILLION) 107

TABLE 69 CHINA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,

2013—2020 ($MILLION) 108

TABLE 70 CHINA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 109

TABLE 71 CHINA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 109

TABLE 72 JAPAN: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,

2013—2020 ($MILLION) 110

TABLE 73 JAPAN: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 111

TABLE 74 JAPAN: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 111

TABLE 75 INDIA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 113

TABLE 76 INDIA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 113

TABLE 77 INDIA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 114

TABLE 78 ROA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 114

TABLE 79 ROA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 115

TABLE 80 ROA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 115

TABLE 81 ROW: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 119

TABLE 82 ROW: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 119

TABLE 83 ROW: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 120

TABLE 84 ROW: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2013—2020 ($MILLION) 120

TABLE 85 COLLABORATIONS/AGREEMENTS/PARTNERSHIPS/ALLIANCES, 2012-2015 132

TABLE 86 NEW PRODUCT LAUNCHES, 2012–2015 133

TABLE 87 ACQUISITIONS, 2012–2015 134

TABLE 88 EXPANSIONS, 2012–2015 135

TABLE 89 OTHER STRATEGIES, 2012–2015 136

List Of Figures, Charts and Diagrams
in Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020

LIST OF FIGURES


FIGURE 1 CANCER DIAGNOSTICS MARKET SEGMENTATION 19

FIGURE 2 GLOBAL CANCER DIAGNOSTICS MARKET : RESEARCH METHODOLOGY STEPS 22

FIGURE 3 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 25

FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 27

FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 27

FIGURE 6 DATA TRIANGULATION METHODOLOGY 29

FIGURE 7 PLATFORM-BASED DIAGNOSTICS TO WITNESS HIGHEST CAGR OF 24.8% FROM 2015 TO 2020 30

FIGURE 8 GLOBAL PLATFORM-BASED CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2015–2020 31

FIGURE 9 GLOBAL CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY 32

FIGURE 10 LARGEST AND FASTEST-GROWING CANCER DIAGNOSTIC APPLICATIONS,

2015-2020 33

FIGURE 11 CANCER DIAGNOSTICS MARKET LIKELY TO GROW AT A CAGR OF 12.9% IN THE FORECAST PERIOD 34

FIGURE 12 CANCER DIAGNOSTICS MARKET, BY REGION AND APPLICATION: NORTH AMERICA WILL DOMINATE THE CANCER DIAGNOSTICS MARKET IN 2015 35

FIGURE 13 ASIA TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 36

FIGURE 14 PLATFORM-BASED TECHNOLOGY LIKELY TO GAIN SIGNIFICANT MARKET SHARE

BY 2020 36

FIGURE 15 CANCER DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES 38

FIGURE 16 MARKET GROWTH WILL BE DRIVEN BY RISING INCIDENCE & PREVALENCE OF BREAST AND LUNG CANCERS 53

FIGURE 17 LUNG CANCER APPLICATION IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD 54

FIGURE 18 NGS, A GROUND-BREAKING TECHNOLOGY IN CANCER DIAGNOSIS 62

FIGURE 19 ULTRASOUND ACCOUNTED FOR THE LARGEST SHARE OF THE CANCER DIAGNOSTICS MARKET FOR IMAGING 76

FIGURE 20 GLOBAL NGS MARKET (FOR CANCER DIAGNOSTICS) SHARE ANALYSIS, BY KEY PLAYER, 2014 121

FIGURE 21 GLOBAL MICROARRAYS MARKET (FOR CANCER DIAGNOSTICS) SHARE ANALYSIS, BY KEY PLAYER, 2014 122

FIGURE 22 GLOBAL FLOW CYTOMETRY (FOR CANCER DIAGNOSTICS) MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014 123

FIGURE 23 GLOBAL MRI IMAGING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014 124

FIGURE 24 GLOBAL CT IMAGING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014 125

FIGURE 25 GLOBAL PET IMAGING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014 126

FIGURE 26 GLOBAL ULTRASOUND IMAGING MARKET SHARE ANALYSIS,

BY KEY PLAYER, 2014 127

FIGURE 27 AGILENT TECHNOLOGIES AND QIAGEN WERE THE MOST AGGRESSIVE PLAYERS 129

FIGURE 28 NEW PRODUCT LAUNCHES WAS THE KEY GROWTH STRATEGY FOR MARKET PLAYERS 130

FIGURE 29 BATTLE FOR MARKET SHARE: COLLABORATIONS/AGREEMENTS/ PARTNERSHIPS/ ALLIANCES WERE KEY STRATEGIES 131

FIGURE 30 GEOGRAPHICAL REVENUE MIX OF KEY PLAYERS IN THE MARKET 137

FIGURE 31 QIAGEN N.V.: COMPANY SNAPSHOT 138

FIGURE 32 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 142

FIGURE 33 GE HEALTHCARE: COMPANY SNAPSHOT 145

FIGURE 34 ABBOTT: COMPANY SNAPSHOT 148

FIGURE 35 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT 150

FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT 159

FIGURE 37 SIEMENS: COMPANY SNAPSHOT 162

FIGURE 38 C.R. BARD, INC.: COMPANY SNAPSHOT 165

Additional Details

Publisher

MarketsandMarkets

Publisher Information

Reference

41623 | MD 3480

Number of Pages

181

Report Format

PDF

MarketsandMarkets Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Is the HER2-positive breast cancer extended adjuvant opportunity big enough to support neratinib's blockbuster forecasts?
Scope Top-line data from the ExteNET study – which were released earlier this week – appear to estab...
28 Jul 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
13 Jul 2014 by FirstWord Pharma USD $695 More Info
The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus
IntroductionThere has been considerable media hype and clinical interest in cancer immunotherapy in ...
01 Jul 2014 by FirstWord Pharma USD $4,995 More Info
Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity?
Scope According to analysts at Barclays, oncology continues to attract around one-third of pharma's ...
28 Apr 2014 by FirstWord Pharma USD $695 More Info
Breast Cancer: New targeted therapies transform treatment - KOL Insight
IntroductionThe introduction of targeted therapies revolutionised the breast cancer market, widening...
10 Feb 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: Bayer's M&A catalyst – is Xofigo a paradigm shifter for the prostate cancer market?
Scope Already positioned as one of the most commercially promising new drug approvals of 2013, Alget...
01 Dec 2013 by FirstWord Pharma USD $695 More Info
KOL Insight: Prostate Cancer: Competition intensifies in race to the top
IntroductionThe Prostate Cancer market has seen a number of progressive changes in recent years. The...
01 Nov 2013 by FirstWord Pharma USD $7,900 More Info
Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top
IntroductionCharting the Future Prostate Cancer Market LandscapeThe prostate cancer market has exper...
01 Nov 2013 by FirstWord Pharma USD $4,995 More Info
Colorectal Cancer -- KOL Insight Module
IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift du...
01 Oct 2013 by FirstWord Pharma USD $7,900 More Info
Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting?
ScopeThe prostate cancer market looks poised to enter its next stage of evolution in 2014, with Medi...
01 Oct 2013 by FirstWord Pharma USD $695 More Info

This report is published by MarketsandMarkets

Download Free Report Summary PDF

Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...